U.S. markets open in 8 hours 35 minutes

Asensus Surgical, Inc. (ASXC)

NYSE American - NYSE American Delayed Price. Currency in USD
0.3050+0.0082 (+2.76%)
At close: 04:00PM EST
0.3150 +0.01 (+3.28%)
After hours: 07:53PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close0.2968
Bid0.0000 x 1100
Ask0.0000 x 1800
Day's Range0.2968 - 0.3100
52 Week Range0.2000 - 0.8600
Avg. Volume1,238,830
Market Cap80.795M
Beta (5Y Monthly)1.44
PE Ratio (TTM)N/A
EPS (TTM)-0.3300
Earnings DateFeb 29, 2024 - Mar 04, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ASXC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Asensus Surgical, Inc.
    Analyst Report: Stryker Corp.Based in Kalamazoo, Michigan, Stryker manufactures and markets medical devices, primarily in the orthopedic market. The Orthopedics segment sells joint reconstructive products (hips, knees and shoulders) and trauma implants. The MedSurg Equipment segment sells powered surgical instruments, surgical navigation systems, endoscopic products, medical video imaging equipment, and hospital beds and patient-handling systems. The Neurotechnology unit includes the neurovascular business as well as the interventional spine and spinal implants business.
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    Asensus Surgical Celebrates 1,000 Senhance Cases Completed at Three Global Hospitals

    The Senhance Surgical System The Senhance Surgical System is designed to increase surgeon control and reduce variability through Augmented Intelligence and deep learning capabilities. RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced the completion of more than 1,000 successful cases each at three hospitals utilizing the Senhance® Su

  • Zacks

    Down -25.24% in 4 Weeks, Here's Why Asensus Surgical (ASXC) Looks Ripe for a Turnaround

    Asensus Surgical (ASXC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

  • GlobeNewswire

    Asensus Surgical Announces Nagoya University Hospital in Japan to Initiate Senhance Surgery Program

    The Fourth Hospital to Initiate a Senhance® Surgical System Dedicated to Pediatric Procedures Senhance® Surgical System Nagoya University Hospital, Japan, initiated a Senhance® Surgical System dedicated to pediatric procedures RESEARCH TRIANGLE PARK, N.C., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that Nagoya University Hospital in Japan has entered